Rumiko Kinoshita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rumiko Kinoshita has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Shinichi Shimizu
Department of Carbon Ion Radiotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
10 shared publications - Hiroki Shirato
Hokkaido University
9 shared publications - Rikiya Onimaru
Department of Radiation Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan
7 shared publications Kentaro Nishioka
Global Center for Biomedical Science and Engineering, Hokkaido University, Sapporo, Japan
5 shared publications- Masayori Ishikawa
Graduate School of Biomedical Science and Engineering, Hokkaido University, Sapporo, Japan
5 shared publications Hidefumi Aoyama
Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan
4 shared publications
Latest Publications
- 3 March 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (3) , 784-789
Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM)
- 3 March 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (3) , 784-789
Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM)
- Open Access
- 29 October 2025
- Published by Springer Nature in Research Square
Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomymatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastatic disease characterized by cystic lung destruction. The existence of increased breast cancer risk among LAM patients, together with the proposed role of estrogen in the onset and progression of LAM, suggests a potential shared pathophysiological mechanism between LAM and breast cancer. We experienced three cases of early-stage breast cancer with LAM. All three cases were treated with breast-conserving surgery followed by radiation therapy and hormone therapy. There were no serious adverse events associated with the radiotherapy, and the patients have progressed without recurrence or metastasis of breast cancer or worsening of LAM in any of the values measured during the follow-up period.
- 29 October 2025
- Published by Springer Nature in Research Square
Open AccessThree cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomymatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastatic disease characterized by cystic lung destruction. The existence of increased breast cancer risk among LAM patients, together with the proposed role of estrogen in the onset and progression of LAM, suggests a potential shared pathophysiological mechanism between LAM and breast cancer. We experienced three cases of early-stage breast cancer with LAM. All three cases were treated with breast-conserving surgery followed by radiation therapy and hormone therapy. There were no serious adverse events associated with the radiotherapy, and the patients have progressed without recurrence or metastasis of breast cancer or worsening of LAM in any of the values measured during the follow-up period.
- 5 April 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 195, 110269
Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes
- 5 April 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 195, 110269
Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes
- Open Access
- 17 March 2024
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 65 (3) , 369-378
Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization
This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10−1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10−1 in IMXT; 0.04, 0.74 and 0.19 × 10−1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10−1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy.
- 17 March 2024
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 65 (3) , 369-378
Open AccessProbability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization
This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10−1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10−1 in IMXT; 0.04, 0.74 and 0.19 × 10−1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10−1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy.
- 12 December 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , e501-e509
Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy
- 12 December 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , e501-e509
Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy
- Open Access
- 3 January 2023
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 64 (2) , 463-470
Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer
Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, alpha-7 HPV and alpha-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPV alpha-7, HPV alpha-9 and negatives. Of the 46 patients, 10 were positive for HPV alpha-7, 21 positive for HPV alpha-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPV alpha-7, HPV alpha-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPV alpha-7 showed statistically significant poorer PC than the HPV alpha-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
- 3 January 2023
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 64 (2) , 463-470
Open AccessDistribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer
Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, alpha-7 HPV and alpha-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPV alpha-7, HPV alpha-9 and negatives. Of the 46 patients, 10 were positive for HPV alpha-7, 21 positive for HPV alpha-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPV alpha-7, HPV alpha-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPV alpha-7 showed statistically significant poorer PC than the HPV alpha-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
- Open Access
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 3 (1) , 20210064
Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?
Objectives: The purpose of this study is to investigate whether verbal instructions are sufficient for bladder volume (BV) control not to deteriorate prostate position reproducibility in image-guided spot scanning proton therapy (SSPT) for localized prostate cancer. Methods: A total of 268 treatment sessions in 12 consecutive prostate cancer patients who were treated with image-guided SSPT with fiducial markers were retrospectively analyzed. In addition to strict rectal volume control procedures, simple verbal instructions to void urine one hour before the treatment were used here. The BV was measured by a Bladder Scan just before the treatment, and the prostate motion was measured by intraprostatic fiducial markers and two sets of X-ray fluoroscopy images. The correlation between the BV change and prostate motion was assessed by linear mixed-effects models and systematic and random errors according to the reproducibility of the BV. Results: The mean absolute BV change during treatment was from −98.7 to 86.3 ml (median 7.1 ml). The mean absolute prostate motion of the patients in the left-right direction was −1.46 to 1.85 mm; in the cranial-caudal direction it was −6.10 to 3.65 mm, and in the anteroposterior direction −1.90 to 5.23 mm. There was no significant relationship between the BV change and prostate motion during SSPT. The early and late genitourinary and gastrointestinal toxicity was minimal with a minimum follow up of 4.57 years. Conclusions: Simple verbal instructions about urination was suggested to be sufficient to control the BV not to impact on the prostate motion and clinical outcomes in image-guided SSPT. Careful attention to BV change is still needed when the seminal vesicle is to be treated. Advances in knowledge: Our data demonstrated that there was no apparent relationship between BV changes and prostate position reproducibility and simple verbal instruction about urination could be sufficient for image-guided SSPT.
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 3 (1) , 20210064
Open AccessAre simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?
Objectives: The purpose of this study is to investigate whether verbal instructions are sufficient for bladder volume (BV) control not to deteriorate prostate position reproducibility in image-guided spot scanning proton therapy (SSPT) for localized prostate cancer. Methods: A total of 268 treatment sessions in 12 consecutive prostate cancer patients who were treated with image-guided SSPT with fiducial markers were retrospectively analyzed. In addition to strict rectal volume control procedures, simple verbal instructions to void urine one hour before the treatment were used here. The BV was measured by a Bladder Scan just before the treatment, and the prostate motion was measured by intraprostatic fiducial markers and two sets of X-ray fluoroscopy images. The correlation between the BV change and prostate motion was assessed by linear mixed-effects models and systematic and random errors according to the reproducibility of the BV. Results: The mean absolute BV change during treatment was from −98.7 to 86.3 ml (median 7.1 ml). The mean absolute prostate motion of the patients in the left-right direction was −1.46 to 1.85 mm; in the cranial-caudal direction it was −6.10 to 3.65 mm, and in the anteroposterior direction −1.90 to 5.23 mm. There was no significant relationship between the BV change and prostate motion during SSPT. The early and late genitourinary and gastrointestinal toxicity was minimal with a minimum follow up of 4.57 years. Conclusions: Simple verbal instructions about urination was suggested to be sufficient to control the BV not to impact on the prostate motion and clinical outcomes in image-guided SSPT. Careful attention to BV change is still needed when the seminal vesicle is to be treated. Advances in knowledge: Our data demonstrated that there was no apparent relationship between BV changes and prostate position reproducibility and simple verbal instruction about urination could be sufficient for image-guided SSPT.
- Open Access
- 16 May 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 95
The clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma
To examine the clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Twenty-one patients with 26 eyes diagnosed with ocular adnexal MALT lymphoma (26 eyes), who were treated in Hokkaido University Hospital, were retrospectively reviewed based on medical records. Out of the 21 patients, 16 patients (21 eyes) received radiation therapy (RT) with a total dose of 30 Gy. All cases eventually achieved complete remission. Eight of these patients (11 eyes: 52.3%) required cataract surgery after RT. The mean age at surgery was 56.8 (40–70) years. The mean latency between RT and the indication for surgery was 43.3 months. The percentage of females was significantly higher in patients who required surgery (P < 0.01), compared with those without surgery. The eyes of patients who received bolus technique on radiation treatment developed cataract more frequently (P < 0.05). In contrast, none of the patients without RT required cataract surgery. Patients with ocular adnexal MALT lymphoma who underwent surgery for radiation cataract were seen more often in relatively young, female patients, and surgery was required about 3 years after RT. A long-term observation may be needed for patients after RT for a tumor. A female sex and the bolus technique may be risk factors for radiation cataract.
- 16 May 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 95
Open AccessThe clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma
To examine the clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Twenty-one patients with 26 eyes diagnosed with ocular adnexal MALT lymphoma (26 eyes), who were treated in Hokkaido University Hospital, were retrospectively reviewed based on medical records. Out of the 21 patients, 16 patients (21 eyes) received radiation therapy (RT) with a total dose of 30 Gy. All cases eventually achieved complete remission. Eight of these patients (11 eyes: 52.3%) required cataract surgery after RT. The mean age at surgery was 56.8 (40–70) years. The mean latency between RT and the indication for surgery was 43.3 months. The percentage of females was significantly higher in patients who required surgery (P < 0.01), compared with those without surgery. The eyes of patients who received bolus technique on radiation treatment developed cataract more frequently (P < 0.05). In contrast, none of the patients without RT required cataract surgery. Patients with ocular adnexal MALT lymphoma who underwent surgery for radiation cataract were seen more often in relatively young, female patients, and surgery was required about 3 years after RT. A long-term observation may be needed for patients after RT for a tumor. A female sex and the bolus technique may be risk factors for radiation cataract.
- Open Access
- 1 March 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-9
Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers
Current adaptive and dose escalating radiotherapy for muscle invasive bladder cancer requires knowledge of both inter-fractional and intra-fractional motion of the bladder wall involved. The purpose of this study is to characterize inter- and intra-fractional movement of the partial bladder wall using implanted fiducial markers and a real-time tumor-tracking radiotherapy system. Two hundred fifty one sessions with 29 patients were analysed. After maximal transurethral bladder tumor resection and 40 Gy of whole bladder irradiation, up to six gold markers were implanted transurethrally into the bladder wall around the tumor bed and used for positional registration. We compared the systematic and random uncertainty of positions between cranial vs. caudal, left vs. right, and anterior vs. posterior tumor groups. The variance in intrafractional movement and the percentage of sessions where 3 mm and 5 mm or more of intrafractional wall movement occurring at 2, 4, 6, 8, 10, and at more than 10 min until the end of a session were determined. The cranial and anterior tumor group showed larger interfractional uncertainties in the position than the opposite side tumor group in the CC and AP directions respectively, but these differences did not reach significance. Among the intrafractional uncertainty of position, the cranial and anterior tumor group showed significantly larger systematic uncertainty of position than the groups on the opposite side in the CC direction. The variance of intrafractional movement increased over time; the percentage of sessions where intrafractional wall movement was larger than 3 mm within 2 min of the start of a radiation session or larger than 5 mm within 10 min was less than 5%, but this percentage was increasing further during the session, especially in the cranial and anterior tumor group. More attention for intrafractional uncertainty of position is required in the treatment of cranial and anterior bladder tumors especially in the CC direction. The optimal internal margins in each direction should be chosen or a precise intrafractional target localization system is required depending on the tumor location and treatment delivery time in the setting of partial bladder radiotherapy.
- 1 March 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-9
Open AccessAnalysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers
Current adaptive and dose escalating radiotherapy for muscle invasive bladder cancer requires knowledge of both inter-fractional and intra-fractional motion of the bladder wall involved. The purpose of this study is to characterize inter- and intra-fractional movement of the partial bladder wall using implanted fiducial markers and a real-time tumor-tracking radiotherapy system. Two hundred fifty one sessions with 29 patients were analysed. After maximal transurethral bladder tumor resection and 40 Gy of whole bladder irradiation, up to six gold markers were implanted transurethrally into the bladder wall around the tumor bed and used for positional registration. We compared the systematic and random uncertainty of positions between cranial vs. caudal, left vs. right, and anterior vs. posterior tumor groups. The variance in intrafractional movement and the percentage of sessions where 3 mm and 5 mm or more of intrafractional wall movement occurring at 2, 4, 6, 8, 10, and at more than 10 min until the end of a session were determined. The cranial and anterior tumor group showed larger interfractional uncertainties in the position than the opposite side tumor group in the CC and AP directions respectively, but these differences did not reach significance. Among the intrafractional uncertainty of position, the cranial and anterior tumor group showed significantly larger systematic uncertainty of position than the groups on the opposite side in the CC direction. The variance of intrafractional movement increased over time; the percentage of sessions where intrafractional wall movement was larger than 3 mm within 2 min of the start of a radiation session or larger than 5 mm within 10 min was less than 5%, but this percentage was increasing further during the session, especially in the cranial and anterior tumor group. More attention for intrafractional uncertainty of position is required in the treatment of cranial and anterior bladder tumors especially in the CC direction. The optimal internal margins in each direction should be chosen or a precise intrafractional target localization system is required depending on the tumor location and treatment delivery time in the setting of partial bladder radiotherapy.
- Open Access
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32 (9) , 1095-1102
NTCP modeling analysis of acute hematologic toxicity in whole pelvic radiation therapy for gynecologic malignancies – A dosimetric comparison of IMRT and spot-scanning proton therapy (SSPT)
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32 (9) , 1095-1102
Open AccessNTCP modeling analysis of acute hematologic toxicity in whole pelvic radiation therapy for gynecologic malignancies – A dosimetric comparison of IMRT and spot-scanning proton therapy (SSPT)